REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 189 filers reported holding REATA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 2.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,141,160 | -0.7% | 21,000 | -11.4% | 1.10% | -4.0% |
| Q1 2023 | $2,155,531 | +139.3% | 23,708 | 0.0% | 1.14% | +140.2% |
| Q4 2022 | $900,667 | +51.1% | 23,708 | 0.0% | 0.48% | +31.9% |
| Q3 2022 | $596,000 | -17.5% | 23,708 | -0.3% | 0.36% | -9.1% |
| Q2 2022 | $722,000 | -7.3% | 23,768 | 0.0% | 0.40% | +12.8% |
| Q1 2022 | $779,000 | -24.9% | 23,768 | -39.5% | 0.35% | -27.8% |
| Q4 2021 | $1,037,000 | -68.9% | 39,312 | +18.7% | 0.49% | -73.1% |
| Q3 2021 | $3,333,000 | -32.3% | 33,127 | -4.8% | 1.80% | -29.9% |
| Q2 2021 | $4,926,000 | +42.0% | 34,802 | +0.0% | 2.57% | +26.9% |
| Q1 2021 | $3,468,000 | -20.2% | 34,787 | -1.0% | 2.03% | -27.5% |
| Q4 2020 | $4,345,000 | +1.5% | 35,152 | -20.0% | 2.80% | -12.1% |
| Q3 2020 | $4,279,000 | -36.7% | 43,927 | +1.3% | 3.18% | -47.2% |
| Q2 2020 | $6,764,000 | -23.4% | 43,352 | +0.4% | 6.02% | -32.0% |
| Q4 2019 | $8,832,000 | – | 43,199 | – | 8.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |